For ESR1 mutation patients, significant PFS improvement is observed with Camizestrant and Elacestrant monotherapy, which have been recommended in multiple guidelines and could become the new cornerstone of endocrine therapy for HR + /HER2 − breast cancer patients. Here, HR is linked to breast cancer.